Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with Psoriasis

With newer biologics, the achievement of complete skin clearance has become an attainable treatment goal for patients with plaque psoriasis. We evaluate how improvements in Psoriasis Area and Severity Index (PASI) responses, particularly at incremental improvements approaching complete skin clearanc...

Descripción completa

Detalles Bibliográficos
Autores: Augustin, Matthias|||0000-0002-4026-8728, Gottlieb, Alice B., Lebwohl, Mark, Pinter, Andreas|||0000-0002-1330-1502, Warren, Richard B.|||0000-0002-2918-6481, Puig Sanz, Lluís|||0000-0001-6083-0952, Warham, Rhys, Lambert, Jérémy, Wiegratz, Susanne, Szilagyi, Balint, Blauvelt, Andrew|||0000-0002-2633-985X
Tipo de recurso: artículo
Fecha de publicación:2024
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:305752
Acceso en línea:https://ddd.uab.cat/record/305752
https://dx.doi.org/urn:doi:10.1007/s13555-024-01261-6
Access Level:acceso abierto
Palabra clave:Biologics
Clinical trials
Psoriasis
Quality of life
id ES_17be2fb436cae4f249d82c556c842bc4
oai_identifier_str oai:ddd.uab.cat:305752
network_acronym_str ES
network_name_str España
repository_id_str
spelling Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with PsoriasisAugustin, Matthias|||0000-0002-4026-8728Gottlieb, Alice B.Lebwohl, MarkPinter, Andreas|||0000-0002-1330-1502Warren, Richard B.|||0000-0002-2918-6481Puig Sanz, Lluís|||0000-0001-6083-0952Warham, RhysLambert, JérémyWiegratz, SusanneSzilagyi, BalintBlauvelt, Andrew|||0000-0002-2633-985XBiologicsClinical trialsPsoriasisQuality of lifeWith newer biologics, the achievement of complete skin clearance has become an attainable treatment goal for patients with plaque psoriasis. We evaluate how improvements in Psoriasis Area and Severity Index (PASI) responses, particularly at incremental improvements approaching complete skin clearance (PASI 100), translate into improvements in health-related quality of life (HRQoL) and patient-perceived symptoms. Data from the BE RADIANT phase 3b trial (NCT03536884) and its open-label extension (OLE), pooled across all study visits and treatments over 16 weeks (randomised patients) and 2 years (patients entering the OLE), were analysed using mixed-effects logistic regression models. Proportions of patients achieving a Dermatology Life Quality Index (DLQI) of 0/1, DLQI item scores of 0, and Psoriasis Symptoms and Impacts Measure (P-SIM) item scores of 0 for itching, scaling, and skin pain at specific PASI improvement levels were estimated. Seven hundred and forty-three patients were randomised to treatment; 654 entered the OLE. Using 16-week pooled data, there were incremental improvements in the proportions of patients estimated by our model to achieve DLQI 0/1 with PASI 100 compared with 95% (PASI = 95%) and 90% (PASI = 90%) improvements in PASI (93.0%, 89.3%, and 83.8% achieving DLQI 0/1, respectively). Estimated proportions achieving DLQI item scores of 0 had the greatest increases at higher PASI improvement levels for Items 1 (itchy, sore, painful, or stinging skin), 2 (embarrassment), and 4 (choice of clothing). Estimated proportions of patients achieving P-SIM = 0 were also higher for PASI 100 (itching: 61.7%; scaling: 82.2%; skin pain: 96.9%) than for PASI = 95% (50.8%; 72.3%; 95.7%) and PASI = 90% (39.8%; 59.5%; 94.0%). Similar benefits of incremental PASI improvements were estimated using 2-year data. Complete skin clearance translated into the greatest benefits to HRQoL and patient-perceived symptoms, over and above skin clearance between 90% and 100%, highlighting the importance of targeting PASI 100 as a treatment outcome for patients with psoriasis.Universitat Autònoma de Barcelona. Departament de Medicina 22024-01-0120242024-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/305752https://dx.doi.org/urn:doi:10.1007/s13555-024-01261-6reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:3057522026-06-06T12:50:31Z
dc.title.none.fl_str_mv Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with Psoriasis
title Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with Psoriasis
spellingShingle Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with Psoriasis
Augustin, Matthias|||0000-0002-4026-8728
Biologics
Clinical trials
Psoriasis
Quality of life
title_short Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with Psoriasis
title_full Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with Psoriasis
title_fullStr Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with Psoriasis
title_full_unstemmed Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with Psoriasis
title_sort Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with Psoriasis
dc.creator.none.fl_str_mv Augustin, Matthias|||0000-0002-4026-8728
Gottlieb, Alice B.
Lebwohl, Mark
Pinter, Andreas|||0000-0002-1330-1502
Warren, Richard B.|||0000-0002-2918-6481
Puig Sanz, Lluís|||0000-0001-6083-0952
Warham, Rhys
Lambert, Jérémy
Wiegratz, Susanne
Szilagyi, Balint
Blauvelt, Andrew|||0000-0002-2633-985X
author Augustin, Matthias|||0000-0002-4026-8728
author_facet Augustin, Matthias|||0000-0002-4026-8728
Gottlieb, Alice B.
Lebwohl, Mark
Pinter, Andreas|||0000-0002-1330-1502
Warren, Richard B.|||0000-0002-2918-6481
Puig Sanz, Lluís|||0000-0001-6083-0952
Warham, Rhys
Lambert, Jérémy
Wiegratz, Susanne
Szilagyi, Balint
Blauvelt, Andrew|||0000-0002-2633-985X
author_role author
author2 Gottlieb, Alice B.
Lebwohl, Mark
Pinter, Andreas|||0000-0002-1330-1502
Warren, Richard B.|||0000-0002-2918-6481
Puig Sanz, Lluís|||0000-0001-6083-0952
Warham, Rhys
Lambert, Jérémy
Wiegratz, Susanne
Szilagyi, Balint
Blauvelt, Andrew|||0000-0002-2633-985X
author2_role author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universitat Autònoma de Barcelona. Departament de Medicina
dc.subject.none.fl_str_mv Biologics
Clinical trials
Psoriasis
Quality of life
topic Biologics
Clinical trials
Psoriasis
Quality of life
description With newer biologics, the achievement of complete skin clearance has become an attainable treatment goal for patients with plaque psoriasis. We evaluate how improvements in Psoriasis Area and Severity Index (PASI) responses, particularly at incremental improvements approaching complete skin clearance (PASI 100), translate into improvements in health-related quality of life (HRQoL) and patient-perceived symptoms. Data from the BE RADIANT phase 3b trial (NCT03536884) and its open-label extension (OLE), pooled across all study visits and treatments over 16 weeks (randomised patients) and 2 years (patients entering the OLE), were analysed using mixed-effects logistic regression models. Proportions of patients achieving a Dermatology Life Quality Index (DLQI) of 0/1, DLQI item scores of 0, and Psoriasis Symptoms and Impacts Measure (P-SIM) item scores of 0 for itching, scaling, and skin pain at specific PASI improvement levels were estimated. Seven hundred and forty-three patients were randomised to treatment; 654 entered the OLE. Using 16-week pooled data, there were incremental improvements in the proportions of patients estimated by our model to achieve DLQI 0/1 with PASI 100 compared with 95% (PASI = 95%) and 90% (PASI = 90%) improvements in PASI (93.0%, 89.3%, and 83.8% achieving DLQI 0/1, respectively). Estimated proportions achieving DLQI item scores of 0 had the greatest increases at higher PASI improvement levels for Items 1 (itchy, sore, painful, or stinging skin), 2 (embarrassment), and 4 (choice of clothing). Estimated proportions of patients achieving P-SIM = 0 were also higher for PASI 100 (itching: 61.7%; scaling: 82.2%; skin pain: 96.9%) than for PASI = 95% (50.8%; 72.3%; 95.7%) and PASI = 90% (39.8%; 59.5%; 94.0%). Similar benefits of incremental PASI improvements were estimated using 2-year data. Complete skin clearance translated into the greatest benefits to HRQoL and patient-perceived symptoms, over and above skin clearance between 90% and 100%, highlighting the importance of targeting PASI 100 as a treatment outcome for patients with psoriasis.
publishDate 2024
dc.date.none.fl_str_mv 2
2024-01-01
2024
2024-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/305752
https://dx.doi.org/urn:doi:10.1007/s13555-024-01261-6
url https://ddd.uab.cat/record/305752
https://dx.doi.org/urn:doi:10.1007/s13555-024-01261-6
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869403940493197312
score 15,812429

Similares en LA Referencia